CONTEXT: The undercarboxylated form of the osteoblast-secreted protein osteocalcin has favorable effects on fat and glucose metabolism in mice. In human subjects, cross-sectional studies suggest a relevant association. OBJECTIVE: We investigated whether changes in undercarboxylated osteocalcin (ucOC) during osteoporosis treatment are associated with changes in metabolic parameters. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS: We measured ucOC in sera from a subset of osteoporotic postmenopausal women who were treated with PTH(1-84) oralendronate (n = 64 and n = 33, respectively) during the Parathyroid Hormone and Alendronate study. MAIN OUTCOME MEASURES: We measured serum adiponectin, leptin, and insulin and analyzed existing data on body weight, fat mass, and serum glucose concentration. Three-month changes in ucOC levels were evaluated as predictors of 12-month changes in indices of fat and glucose metabolism. RESULTS:ucOC levels increased with PTH(1-84) and decreased with alendronate administration (P ≤ 0.01 for both treatment groups). Three-month change in ucOC was inversely associated with 12-month changes in body weight (standardized β = -0.25, P = 0.04) and fat mass (β = -0.23, P = 0.06), after adjustment for the treatment group. Three-month change in ucOC was positively associated with a 12-month change in adiponectin (β = 0.30, P = 0.01), independent of change in fat mass. There were no interactions between treatment and change in ucOC on changes in weight, fat mass, or adiponectin. CONCLUSIONS:PTH(1-84) increases and alendronate decreases ucOC levels. Changes in ucOC induced by PTH(1-84) and alendronate are associated with changes in metabolic indices. These associations are consistent with observations from animal models and support a role for ucOC in the skeletal regulation of energy metabolism in humans.
RCT Entities:
CONTEXT: The undercarboxylated form of the osteoblast-secreted protein osteocalcin has favorable effects on fat and glucose metabolism in mice. In human subjects, cross-sectional studies suggest a relevant association. OBJECTIVE: We investigated whether changes in undercarboxylated osteocalcin (ucOC) during osteoporosis treatment are associated with changes in metabolic parameters. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS: We measured ucOC in sera from a subset of osteoporotic postmenopausal women who were treated with PTH(1-84) or alendronate (n = 64 and n = 33, respectively) during the Parathyroid Hormone and Alendronate study. MAIN OUTCOME MEASURES: We measured serum adiponectin, leptin, and insulin and analyzed existing data on body weight, fat mass, and serum glucose concentration. Three-month changes in ucOC levels were evaluated as predictors of 12-month changes in indices of fat and glucose metabolism. RESULTS: ucOC levels increased with PTH(1-84) and decreased with alendronate administration (P ≤ 0.01 for both treatment groups). Three-month change in ucOC was inversely associated with 12-month changes in body weight (standardized β = -0.25, P = 0.04) and fat mass (β = -0.23, P = 0.06), after adjustment for the treatment group. Three-month change in ucOC was positively associated with a 12-month change in adiponectin (β = 0.30, P = 0.01), independent of change in fat mass. There were no interactions between treatment and change in ucOC on changes in weight, fat mass, or adiponectin. CONCLUSIONS:PTH(1-84) increases and alendronate decreases ucOC levels. Changes in ucOC induced by PTH(1-84) and alendronate are associated with changes in metabolic indices. These associations are consistent with observations from animal models and support a role for ucOC in the skeletal regulation of energy metabolism in humans.
Authors: May Faraj; Peter J Havel; Steve Phélis; David Blank; Allan D Sniderman; Katherine Cianflone Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: Bu B Yeap; S A Paul Chubb; Leon Flicker; Kieran A McCaul; Peter R Ebeling; John P Beilby; Paul E Norman Journal: Eur J Endocrinol Date: 2010-05-25 Impact factor: 6.664
Authors: W S Yang; W J Lee; T Funahashi; S Tanaka; Y Matsuzawa; C L Chao; C L Chen; T Y Tai; L M Chuang Journal: J Clin Endocrinol Metab Date: 2001-08 Impact factor: 5.958
Authors: Jenny M Kindblom; Claes Ohlsson; Osten Ljunggren; Magnus K Karlsson; Asa Tivesten; Ulf Smith; Dan Mellström Journal: J Bone Miner Res Date: 2009-05 Impact factor: 6.741
Authors: A D Anastasilakis; Z Efstathiadou; E Plevraki; G N Koukoulis; A Slavakis; M Kita; A Avramidis Journal: Horm Metab Res Date: 2008-06-13 Impact factor: 2.936
Authors: E Lerchbaum; V Schwetz; S Pilz; T B Grammer; M Look; B O Boehm; B Obermayer-Pietsch; W März Journal: Osteoporos Int Date: 2012-07-10 Impact factor: 4.507
Authors: Corey J Cain; Joel T Valencia; Samantha Ho; Kate Jordan; Aaron Mattingly; Blanca M Morales; Edward C Hsiao Journal: Endocrinology Date: 2016-02-22 Impact factor: 4.736
Authors: C O Tan; R A Battaglino; A L Doherty; R Gupta; A A Lazzari; E Garshick; R Zafonte; L R Morse Journal: Osteoporos Int Date: 2014-07-01 Impact factor: 4.507